In the subgroup analysis that stratified patients by concomitant use with other GLDs, the effect of SGLT2 inhibitors on AF risk reduction was observed among patients who had not used thiazolidinediones and/or sulfonylureas in the baseline. The gene discussed is SLC5A2; the disease is atrial fibrillation.